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Abstract.  A new member of the thrombospondin gene 
family, designated thrombospondin-4, has been 
identified in the Xenopus laevis genome. The predicted 
amino acid sequence indicates that the protein is simi- 
lar to the other members of this gene family in the 
structure of the type 3 repeats and the COOH-terminal 
domain. Thrombospondin-4 contains four type 2 
repeats and lacks the type 1 repeats that are found in 
thrombospondin-1 and 2.  The amino-terminal domain 
of thrombospondin-4 has no significant homology with 
the other members of the thrombospondin gene family 
or with other proteins in the database. RNAse protec- 
tion analysis establishes that the initial expression of 
Xenopus thrombospondin-4 is observed during neuru- 
lation. Levels of mRNA expression increase twofold 
during tallbud stages but decrease by the feeding tad- 
pole stage. The size of the thrombospondin-4 message 
is 3.3 Kb and 3.4 Kb in the frog and human, respec- 
tively. Northern blot analysis of human tissues reveals 
high levels of thrombospondin-4 expression in heart 
and skeletal muscle, low levels in brain, lung and pan- 
creas and undetectable levels in the placenta, liver and 
kidney, These data establish the existence of a new 
member of the thrombospondin gene family that may 
participate in the genesis and function of cardiac and 
skeletal muscle. 
p 
LATELET thrombospondin  is  a  420,000-D  glyco- 
protein that is structurally and functionally similar 
to  the adhesive  glycoproteins  (Lawler  and Hynes, 
1986). Multiple structural domains can be discerned on an 
electron microscopic level (Galvin et al.,  1985; Lawler et 
al.,  1985). Globular  domains  at  the  NH2  and  COOH- 
terminals are involved in the interaction of thrombospond'm 
with the cell surface (Gartner et al., 1984; Dixit et al., 1985; 
Clezardin et al.,  1988; Sun et al.,  1989; Kosfeld et al., 
1991). The central portion of the molecule is composed of 
multiple copies of structural motifs found in other proteins 
(Lawler and Hynes, 1986)..~a~no acid sequences that have 
been shown to mediate cellular attachment are also present 
in the central portion of the molecule (Rich et al.,  1990; 
Aseh et al.,  1992; Prater et al.,  1991; Tuszynski  et al., 
1992). In addition,  thrombospondin  contains a region that 
is rich in calcium binding sites and that contains the arg-gly- 
asp (RGD) sequence that promotes the adhesion of some cell 
types (Lawler and Simons,  1983; Lawler and Hynes, 1986; 
Lawler et al.,  1988). 
Thrombospondin has been shown to modulate the attach- 
ment of a variety of cell types in vitro (Varani et al., 1986, 
1988; Roberts et al., 1987; Santoro,  1987; Tuszynski et al., 
1987; Lawler et al., 1988; Neugebauer et al., 1991; O'Shea 
et al., 1991; Stomski et al., 1992). For some cells, the inter- 
action with thrombospondin  involves the concurrent partiei- 
pation of several domains within the molecule and multiple 
receptors on the cell surface (Asch et al., 1991; Stomski et 
al.,  1992). The  NH2-terminal  heparin-binding  domain 
binds to proteoglycans including syndecan and to cell sur- 
face sulfatides  (Roberts  et al.,  1985; Sun  et al.,  1989). 
Thrombospondin also interacts with CD36 or platelet glyco- 
protein IV (Legrand et al., 1991; Asch et al., 1991; Stomski 
et al.,  1992). Several integrin  receptors, including  Otnb/33, 
UJ33, and ot~31 have been reported to bind thrombospondin 
(Lawler et al., 1988; Lawler and Hynes, 1989; TUszynski et 
al.,  1989, 1991; Karczewski et al.,  1989; Stomski et al., 
1992). In addition, ~,/31~ and a complex of/31 with a novel 
t~ subunit have been reported to be involved in neurite out- 
growth (Neugebauer et al., 1991). Through these, and yet to 
be identified interactions, thrombospondin can modulate  cell 
migration, angiogenesis and neurite outgrowth. 
The 185,000-D thrombospondin polypeptides are encx~ed 
by two distinct genes, designated THBS/and THBS2 (Born- 
stein et al., 1990, 1991a, 1991b; Wolf et al., 1990). To date, 
partial  or complete eDNA sequences are available for hu- 
man,  mouse,  and  frog  thrombospondin-1,  and  human, 
mouse and chicken thrombospondin-2  (Lawler and Hynes, 
1986; Bornstein et al., 1990, 1991a, b; Lawler et al., 1991a, 
b; Urry et al., 1991). The overall molecular architecture of 
thrombospondin-1  and  2  are  equivalent.  The  predicted 
amino acid sequences are very similar in the type 1, 2 and 
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terminal domains of mouse thrombospondin-1 and 2 are only 
32%  identical  (Bornstein  et al.,  1991a,  b).  Phylogenetic 
analysis based on progressive sequence alignment and com- 
parison based on parsimony indicates that the gene duplica- 
tion that produced the thrombospondin-1 and 2  genes oc- 
curred 583  million years ago (J.  Lawler, M. Duquette, L. 
Urry,  K.  McHenry,  and  T.  Smith,  submitted  for publi- 
cation). 
In this paper, we describe the cloning and sequencing of 
a new member of the thrombospondin gene family. This pro- 
tein appears to have been produced by a gene duplication 
event that occurred 925 million years ago (J. Lawler et al., 
1993).  Whereas the type 3 repeats and the COOH-terminal 
domain are similar to those of thrombospondin-1 and 2, this 
protein contains four type 2 repeats, instead of three, and 
lacks the type 1 repeats and the region of homology with 
procollagen.  We also  show that this new member of the 
thrombospondin gene family is expressed at high levels in 
adult heart and  skeletal muscle.  This distribution distin- 
guishes  this protein  from the  recently identified protein, 
designated thrombospondin-3 (Vos et al.  1992).  Based on 
the  number of differences between a  partial  sequence of 
mouse  thrombospondin-3  and  the  protein  that  we  have 
cloned, and on differences in the tissue distribution, we pro- 
pose that the protein that is described here should be desig- 
nated thrombospondin-4. In addition, we report that throm- 
bospondin-4  mRNA  is  first  expressed  in  neurula  stage 
Xenopus laevis embryos consistent with a possible role for 
this protein in heart and skeletal muscle formation. 
Materials and Methods 
Degenerate Oligonucleotides 
The mouse thrombospondin-1, chicken thrombospondin-2 and frog throm- 
bospondin-1 clones were isolated by screening libraries with existing probes 
for other species at low stringency (Lawler et al.,  1991a,  b; Urry et al., 
1991). We then aligned these sequences with the human thrombospondin-1 
sequence and identified two regions that are highly conserved in terms of 
the nucleotide sequence. Based on these sequences, degenerate oligonucle- 
otides were synthesized and used as primers for the PCR. These sequences 
fall in the type 3 repeats and the COOH-terminal region of the molecule 
(Table I). 
Polymerase Chain Reaction 
Aliquots (1, 5 and 25 #1) ofa Xenopus laevis stage 45 eDNA library (DeSi- 
mone, unpublished observations) were brought to a final volume of 71.5/~1 
with H20. The samples were heated to 70"C for 5 rain then cooled on ice. 
To each sample,  10 #1 of 10x  reaction buffer (Cetus Corp.,  Emeryville, 
CA), 6/zl of 25 mM MgC12, 16 #1 of dNTPs and 300 pmol of primers were 
added.  The  reaction  mixture  was  heated  to  95"C  for 5  min and  then 
equilibrated to the annealing temperature (37-48~  TAQ polymerase (2.5 
U) was added and the sample was heated to 72~  for 3 min. The amplifica- 
tion cycles were (a) incubate at 94"C for 1 min and 20 s, (b) incubate at 
48~  for 2 rain, (c) ramp to 72~  over 2 rain, and (d) incubate at 72~ 
for 3 min. This cycle was repeated 30-40 times; finally the sample was in- 
cubated at 72"C for 7 rain. The PCR products were separated by agarose 
gel  electrophoresis  and  the  appropriately  sized  products,  based  on  the 
thrombospondin-1 and 2 sequences, were subcloned into pBlueseript KS or 
SK (Stratagene Corp.,  LaJolla, CA). 
Cloning and Sequencing 
To establish the validity of the thrombospondin-4 clone and to complete the 
sequence,  we screened the Xenopus/aev/s state 45 library with the PCR 
Table I. Oligonucleotides  for Degenerate PCR 
Forward primer (106T) 
T  T  T  A  T  T  T  A  T 
GACTGAATTCC  AA  GC  AACCAGGCTGA  CA  GA  AA  GA  GG 
C  C  C  C  C  C  C  G  C 
Reverse primer (107T) 
T  A  A  T  A 
CTAGGAATTCCTG  CCTGG GTGTTTCC GT  TGCCA 
G  G  G  G  G 
product as the probe. The probe was labeled with digoxigenin-dUTE and 
hybridization performed using the Genius Kit following the supplier's pro- 
tocols (Boehringer Mannheim Corp.,  Indianapolis, IN).  Positive plaques 
were taken through successive rounds of screening with the same probe at 
progressively lower plaque densities. The purified plaques were amplified 
to yield high titre plate stocks. Because the library was constructed in the 
XZAPII vector pBluescript II SK, the inserts were excised with helper phage 
and grown up directly following the supplier's protocols (Stratagene Corp.). 
BamHI and EcoR1  fragments were subcloned into pBluescript II SK and 
KS.  All sequencing was done by the chain termination method of Sanger 
et al. (1977) with Sequenase reagents (US Biochemical Corp., Cleveland, 
OH).  The ends of all clones and subclones were sequenced with the re- 
mainder of the sequence being determined using synthetic oligonucleotides 
as  primers.  The  sequence  of thrombospondin-4  was  obtained  on  both 
strands. 
The largest clone that we obtained from screening the stage 45 library 
was 2.8 kb. To complete the sequence, we have used a 580 bp PstI-StuI frag- 
ment of the XS9 clone to screen a Xenopus laevis stage 22 library (the gener- 
ous gift of Dr. Douglas Melton, Department of Biology and Molecular Biol- 
ogy, Harvard University, Cambridge, MA). Eight clones were isolated and 
phage DNA  was  prepared  as  described previously  (Lawler  and Hynes, 
1986). Of these clones, one clone (designated XM15) contains additional 
sequence at the 5' end of the TSP-4B family (Fig.  1). 
Preparation of  Probe  for Human Thrombospondin-3 
The genomic clone GPEM-2 was kindly provided by Dr. Sandra Gendler 
(Imperial Cancer Research Fund, London; Lancaster et al.,  1990). BamHI 
fragments of GPEM-2 were subcloned into pBluescript KS and the ends of 
each clone were sequenced. One of these clones contained sequences that 
were homologous to the 3' end of the thrombospondin-1, 2 and 4. Based on 
this homology, the position of the 5' end of the last exon was determined. 
The 3' end of this exon was taken to be the polyadenylation signal. Oligonu- 
cleotides that primed at the 5' and 3' ends of the last exon were used to am- 
plify and clone a 293 bp DNA segment that corresponds to the last exon 
of the human thrombospondin-3. 
Northern Blot Analysis 
The Xenopus thrombospondin-4 clone XF3 was digested with EcoR1 and 
Xhol and the insert purified. The human thrombospondin-1 probe was the 
human full-length eDNA (Lawler et al.,  1992). The PCR product for the 
last exon of thmmbospondin-3 and the fl-actin probe (Clontech, Palo Alto, 
CA) were radiolabeled directly. All probes were radiolabeled with the Mul- 
tiprime DNA Labeling System (Amersham Corp., Arlington Heights, IL). 
A Northern blot that was prepared with Poly A+ RNA from adult human 
heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas was 
obtained from Clontech. The blot was prebybridized and hybridized as de- 
scribed previously (Lawler and Hynes,  1986). 
Construction of  Probes  for RNAse Protection 
Templates for the synthesis of antisense thrombospondin-4 transcripts were 
prepared by linearizing a BamHI subclone of clone XF3 with EcoR1. A stan- 
dard in vitro transcription reaction was carried out using 0.5 #g of template 
and 20 U of T7 RNA polymerase (Promega Corp., Madison, WI) as de- 
scribed in DeSimone et al. (1992). Transcripts prepared using this template 
were r~355 nucloatides in length and protected a fragment of '~ 300 nucleo- 
tides.  EFlc~  template was prepared by digesting a PstI-Sacl fragment of 
Xenopus EFI-tx cloned into pSP65 (Krieg et al., 1989) with AluI. Antisense 
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polymerase  (Promega  Corp.).  This probe  protects  a  fragment of '-75 
nucleotides.  Probes were labeled by the incorporation of [c~-32P]rUTP  dur- 
ing the synthesis reaction (800 Ci/mmol;  ICN Biomedicals  Inc.,  Costa 
Mesa, CA) and purified on a 5% polyacrylamide denaturing gel. 
RNAse Protection Analysis 
Total RNA was isolated from embryos exactly as described in DeSimone 
et al.  (1992).  Embryo equivalents  of total RNA were then hybridized to 
50000 cpm of  purified probe. Hybridization was carried out in the presence 
of 80%  formamide,  0.4 M  NaCI,  40 mM Pipes (piperazine-N,N'-bis-2- 
ethanesulfonic  acid), and 1 mM EDTA at 45~  for at least 12 h. Digestion 
of unhybridized probe and electrophoresis was carried out exactly as de- 
scribed in DeSimone r  al. (1992), except that 47 U of RNAse A and 344 
U RNAse TI (Boehringer Mannheim Corp.) were used per 350 #1 RNAse 
reaction. 
Results 
Identification of Thrombospondin-4 
Degenerate PCR using the Xenopus laevis stage 45 library 
has produced four distinct sequences that are related to the 
thrombospondins. Two of the four sequences correspond to 
the two copies of  the thrombospondin-1 gene that are present 
in the Xenopus genome (Urry et al., 1991). The Xenopus ge- 
nome  duplicated  •30  million  years  ago  (Bisbee  et  al., 
1977). In some cases, both copies of the gene are expressed 
(e.g., DeSimone and Hynes, 1988). To date, the thrombo- 
spondin-1  sequences represent the majority of the products 
that we have obtained.  However, two PCR products com- 
prise sequences that are related to, but clearly distinct from 
thrombospondin-1. The sequences of these two PCR prod- 
ucts are very similar to each other suggesting that they repre- 
sent the two copies of a newly identified gene in the Xenopus 
genome. 
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Figure 1. Alignment of  Xenopus  thrombospondin-4 clones. Restric- 
tion endonuclease sites are indicated for the two families (TSP-4A 
and TSP-4B). The clones that have been isolated in the first (XF1- 
XF4),  second  (XSS-XS10), and  third  (XTI1-XTI4) rounds  of 
screening have been grouped into their appropriate family by re- 
striction endonuclease mapping and nucleotide sequencing. 
To establish that these sequences are in fact derived from 
the Xenopus library and to obtain more nucleotide sequence, 
we  have  prepared  a  probe  from  the  PCR  product  and 
screened the library. A screen of 120000 plaques produced 
four positive clones that range in size from 1.7 to 2.3 kb (Fig. 
1, XF1-XF4).  As shown in Fig. 1, the restriction maps of the 
clones  indicate  that  two  distinct  gene  products  can  be 
identified. The longest clone for each gene (XF1  and XF3) 
has been sequenced on both strands.  The sequence of the 
PCR products is included in the sequences of these clones. 
These data confirm that the PCR product is derived from the 
Xenopus library and not from another contaminating source. 
When clone XF3 is used to probe a Northern blot of Xenopus 
stage 17 RNA, a 3.3 kb band is observed (Fig. 2). Because 
the message size is greater than the length of clone XF3 and 
the reading frame is open at the 5' end of  the predicted amino 
acid sequence for clone XF3, the library was rescreened with 
the EcoR1 fragment of clone XF1. This screen produced six 
additional clones (XS5-XS10,  Fig.  1).  Clone XS9 has been 
sequenced on both strands. Clone XS9 is ,,o469 nucleotides 
smaller than the message and the reading frame is open at 
the 5' end of the predicted amino acid sequence. The library 
has been rescreened with the EcoR1 to BamHI fragment of 
XS9.  Four  additional  clones  have  been  isolated  (XTll- 
XT14); however, they do not contain additional nucleotide 
sequence. 
To obtain additional 5' sequence, a Xenopus laevis stage 
22 library was screened. Restriction endonuclease mapping 
indicated that one of the clones (XM15) that was isolated 
contained additional 5' sequence for the TSP-4B family (Fig.  1). 
Determination of  Nucleotide Sequence 
The clones XF3, XS9, and XM15 have been used to deter- 
mine the nucleotide sequence ofXenopus thrombospondin-4 
on both strands. The sequence is 3,120 nucleotides in length. 
A single open reading frame exists between nucleotides 103 
and 2,970 (Fig. 3). There is a short (140 bp) 3' untranslated 
region that ends with a continuous series of adenosines. An 
AATAAA consensus polyadenylation signal is observed up- 
stream of the poly A sequence. The first 120 bp of the se- 
quence contains stop codons in all three reading frames. The 
sequence is  180 bp smaller than the message size that is 
lqgure 2. Northern blot of  Xenopus stage 
17 RNA. Two micrograms of  total stage 
17 mRNA was electrophoresed and blot- 
ted. The blot was probed with the XF3 
clone.  The positions  and  sizes of the 
markers are indicated on the letL 
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61:  TCTGCTGAGCTGCTAAAGGCTAATTCCATTGCAGAAGTCAAGATGCCTAGACGAAAAGGC 
-24:  M  P  R  R  K  G 
121:  TTGTGTCTATTCCTACAGATGTTACTTCTTCATCTTTATGGAGTGTGTCAAGCCCAGCCA 
-18:  L  C  L  F  L  Q  M  L  L  L  H  L  u  G  V  C  Q  A/kQ  P 
181:  AATTATCAAGTCTTCGATCTTCTATCCGTGTCGGTTCAAAGGCAGGTCACCTCTTTCCTT 
3:  N  Y  Q  V  F  D  L  L  S  V  S  V  Q  R  Q  V  T  S  F  L 
241:  CAAAG  CG  CACTGAG  CA~TCCTTCCATGAATGAGGTGTATGTCTTGTCAACTTTCAAA  CTG 
23:  Q  S  A  L  S  N[~  P  S  M  N  E  V  Y  V  L  S  T  F  K  L 
301:  CAG  CCC~GTC~CAG'PI'ACG~I'~f  C~At'~I~TA'I~  C  ~C C~GTGA  C~CAG  CAGGT~ 
43:  Q  P  K  S  T  V  T  L  F  G  L  Y  S  T  S  D  N  S  R  F 
361:  TTTGAAT~CACAGTTATGGGT  CG~T2d%ACAAAGCCTCT~ACGATACCTCCGGAGTGAT 
63:  F  E  F  T  V  M  G  R  L  N  K  A  S  L  R  Y  L  R  S  D 
421:  GGGAAGTTACACTCAGTC~AAT~GCT~GACATAGCTGATGGGAAGCAGCACGCG 
83:  G  K  L  H  S  V  F  F  N  K  L  D  I  A  D  G  K  Q  H  A 
481:  CTTCTGTTGCACCTGAGCGGCTTACACCGGGGCGCAACGTTTGCAAAGCTCTACATAGAC 
103:  L  I;  L  H  L  S  G  L  H  R  G  A  T  F  A  K  L  u  I  D 
541:  TGT~KTCCGACAGGTGTTGTTGAAGATCTACCCCGGCCGTTATCAGGGATAAGGCTCAAC 
123:  C  ~)  P  T  G  V  V  E  D  L  P  R  P  L  S  G  I  R  L  N 
601:  ACAGGGTCTGTGCA  CTTAAGAACA  CTA  CAGAAAAAGGGACAGGATTCCATGGATGAATTA 
143:  T  G  S  V  H  L  R  T  L  Q  K  K  G  Q  D  S  M  D  E  L 
661:  AAACTGGTAATGGGAGGCACTCTGTCCCAGGTAGGAGC2tATACAAGAATGTTTTATG  CAG 
163:  K  L  V  M  G  G  T  L  S  E  V  G  A  I  Q  E  C  F  M  Q 
721  : AAAAGTGAAGCCGGACAGCAGACAGGTGACGTCAGCAGACAGTTGATTGGCCAGATAACC 
183  :  K  S  E  A  G  Q  Q  T  G  D  V  S  R  Q  L  I  G  Q  I  T 
781:  CAAATGAATCAGATGCTGGGAGAGCTCCGAGATGTCATGAGACAG  CAG  GTGAAAGAGACC 
203:  Q  M  N  Q  M  L  G  E  L  R  D  V  M  R  Q  Q  V  K  E  T 
841:  ATGTTCTTGAGAAACACCATTGCAGAATGCCAGGCCTGTGGCTTAGGTCCTGACTTCCCA 
223:  M  F  L  R  N  T  I  A  E  C  Q  A  C  G  L  G  P  D  F  P 
901:  TTGCCAACCAAAGTTCCCCAGCGCCTAGCCACCACTACACCTCCAAAGCCTCGATGTGAT 
243:  L  P  T  K  V  P  Q  R  L  A  T  T  T  P  P  K  P  R  C  D 
961:  G  CAACT~CATGT~ CAGAC,  GAGTG  C~T,  GTGCATTGATACAGAG  GGCG  GC~C CAATGTG  GG 
263:  A  T  S  C  F  R  G  V  R  C  I  []  T  E  G  G  F  Q  C  G 
1021:  CCG  TGTCCTGAAGGCTATACAGGCAACGGTGTCATTTGTACTGATGTGGATGAGTGTCGG 
283:  P  C  P  E  G  Y  T  G  N  G  V  I  C  T  D  V  D  E  C  R 
1081:  TTGAATCCATGTTTCCTTGGTGTACGTTGCATAA~CACTTCTCCGGGTTTCAAATGTGAG 
303:  L  N  P  C  F  L  G  V  R  C  I~  T  S  P  G  F  K  C  E 
1141:  AGCTGCCCTCCCGGGTACACTGGATCCACAATTCAAGGGATTGGCATTAACTTTGCCAAG 
323:  S  C  P  P  G  Y  T  G  S  T  I  Q  G  I  G  I  N  F  A  K 
1201:  C  AAATAAG  CAGGTTTGCACAGATACCAATGAATGTGAAAATGGAAGAAATGGAGGGTGT 
343:  Q  N  K  Q  V  C  T  D  T  N  E  C  E  N  G  R  N  G  G  C 
1261:ACATCC~TTCTCTTTGCAT~TACGATG~ATCTTTCC~G~CAAAC~ 
363:TSNSLCI~TMGSFRCGGCKP 
1321:GG~A~TCC~ATC~TAAAA~C~C~A~GC~CCGTCA~GACAG 
383:GYVGDQIKGCKPEKSCRHGQ 
1381:  ~TCCGTGTCA~C~GTGCTCAG~CAGAGGAA2kAGGACGGTGACGT~CCTGCACT 
403:NPCHASAQCSEEKDGDVTCT 
1441:  TGTTCAGTCGGTT~GCCGGC~AC~G~CAAAGATACTGATA~GATGGC 
423:CSVGWAGNGYLCGKDTDIDG 
1501:  TACCCGGA~GCC~GC~TGTCCAGAT~G~GCAAAAAGGAC~CTGTGTATAT 
443:u 
1561:  GTTC~CGGGTC~G~GACA~GAT~GAT~TTGGAGATGCTTGTGATG~ 
463:VPNSGQEDTDKDNIGDACDE 
1621:GA~CGGA~GAGAT~TATC~TGAGCA~A~GTGTGCTGG~GCC~CATC 
483:DADGDGILNEQDNCVLAANI 
1681:GA~AGAAAAACAGTGAC~GATATA~G~A~C~G~AC~CTGCCG~CC 
503:DQKNSDQDIFGDACDNCRLT 
1741:  CTC~TGACC~G~ACACAGAC~TGACGGG~AGATG~GTGACGATGAC 
523:LNNDQRDTDNDGKGDACDDD 
1801:  A~GATGGAGATGGCATC~G~TATCTTGGAT~GC~GAGAG~CC~TGGAC 
543:MDGDGIKNILDNCQRVPNVD 
1861:  CAG~GAC~GATGGAGA~GAG~GGTGATATATGTGA~G~GTC~GACATCATA 
563:QKDKDGDGVGDICDSCPDII 
1921:~TCCAA~CCAGT~GA~GA~TGAC~G~GGAGATTC~GTGATA~CC~ 
583:NP~)QSDIDNDLVGDSCDTNQ 
1981:  GACAGCGATGGTGATGGT~CCAGGACAGCACAGAC~CTGCCCCA~GTGAT~CAGC 
60~:DSDGDGHQDSTDNCPTVINS 
2041:  ~CCAGCTCGA~GA~GGACGG~TC~AGATG~ACGATGATGATGAT~C 
623:NQLDTDKDGIGDECDDDDDN 
2101:  GATGG~CC~ATACTGTTC~CCCGGA~GAT~T~C~CCCA 
643:DGIPDTVPPGPDNCKLVpNp 
2161:~GCA~A~A~AC~A~AGTCGGAGACGT~G~A~CCGATTTTGACCAG 
663:GQEDDNNDGVGDVCEADFDQ 
2221: GACACGGTCA~AC~GACG~GCCC~AAAATG~GAGATCACCCTGACAGAT 
683:DTVIDRIDVCPENAEITLTD 
2281:  ~CAGAG~ATCA~ACTGTAGTTCTGGATCC~AGATGCCCA~ATCC~C 
703:FRAYQTVVLDPEGDAQIDPN 
2341:T~A~GTT~G~C~TGGAGA~GTGCAGACGA~CAGTGACCCTGGA~G 
723:WIVLNQGMEIVQTMNSDPGL 
2401:  GCAGTTGG~ACACAGCA~AG~GA~CGAGGG~CATTCCACGTG~CACC 
743:AVGYTAFNGVDFEGTFHVNT 
2461:  ATGACGGATGATGA~AC~GGT~CATCT~GGTTATCAGGACAGTTC~GCTT~AT 
763:MTDDDYAGFIFGYQDSSSFY 
Figure 3. The nucleotide sequence and corresponding amino acid sequence of Xenopus thrombospondin-4. The predicted site for signal 
sequence cleavage is indicated (open triangle). The termination codon TAA and the polyadanylation signal AATAAA are underlined. The 
sites for potential N-linked glyeosylation are circled and the site for potential ~-hydroxylation is boxed. Note that asparagine(314) could 
be either glycosylated or ~-l~xlmxylated. These sequence data are available from EMBL/GenBank/DDBJ under accession number,  Z19091. 
predicted by Northern blotting.  Thus, the sequence that is 
presented here appears to lack •180  bp of 5' untranslated se- 
quence. 
Amino Acid Sequence 
An  open  reading  frame  that  is  931  amino  acids  long  is 
predicted from the nucleotide sequence of Xenopus throm- 
bospondin-4  (Fig.  3).  The first 24 amino acids appear  to 
comprise a signal sequence. The predictive algorithm of von 
Heijne (1986)  indicates that the signal sequence would be 
cleaved after alanine(-1)  and that glutamine(1)  is the NH2- 
terminal of the mature thrombospondin-4 peptide. The ma- 
ture  thrombospondin-4 peptide has a molecular weight of 
102,143  and  an  isolectric  point  of  4.2,  before  post- 
translational  modifications.  As with the other members of 
the thrombospondin gene family that have been sequenced, 
the majority of cysteine residues are located in the center one 
third  of the  molecule.  Two types  of repeating  sequences, 
designated homology type 2 and 3 occur within the amino 
acid sequence (see below). There are five potential sites for 
N-linked glycosylation, although two of them include a pro- 
line residue and are less likely tobe used and one of them 
also fits the consensus for B-hydroxylation  (Fig. 3; Hubbard 
and Ivatt,  1981;  Stenflo et al.,  1988). 
The first  282  amino acids  of the thrombospondin-4  se- 
quence have very little homology with human thrombospon- 
din-1  (Lawler and Hynes,  1986).  Whereas amino acid se- 
quences GKQH and LYIDC are present in both sequences 
and the positions of the cysteine residues are similar, we have 
not detected regions of homology with the heparin-binding 
motifs of thrombospondin-1  (Lawler et al.,  1992). 
Four adjacent type 2 repeats can be identified on the basis 
of the positions of the cysteine residues (Fig. 4). The overall 
homology with other thrombospondins is low in this region 
and the introduction of several gaps is necessary to optimize 
the  alignments.  However,  the  second  type  2  repeat  of 
thrombospondin-4 is similar to those of thrombospondin-1 
and 2, in that thirteen residues are inserted between the last 
two cysteine residues. In addition, a consensus sequence for 
~/-hydroxylation can be identified in the second type 2 repeat 
of thrombospondin-1,  2 and 4 (see Discussion). The first and 
third type 2 repeats of thrombospondin-4 also contain con- 
sensus sequences for/~-hydroxylation (Fig.  3). 
The  type  3  repeats  of Xenopus thrombospondin-4  are 
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783:  V  V  M  W  K  Q  T  E  Q  T  u  W  Q  A  T  P  F  R  A  V 
2581:  G  CAGAG  CCTGGAATCCAACTGAAGGCTGTGAAATCCAAGTCAGGAC  C  CGGGGAACATCTG 
803:  A  E  P  G  I  Q  L  K  A  V  K  S  K  S  G  P  G  E  H  L 
2641:  AGGAACGCTCTGTGG  CACACAGGAGACACCAATGATCAAGTGAGG  CTGCTCTGGAAAGAC 
823:  R  N  A  L  W  H  T  G  D  T  N  D  Q  V  R  L  L  W  K  D 
2701:  C  CCAGGAATGTCGGCTGGAAAGACAAAGTCTCCTACCGCTGGTTCTTACAGCACAGG  C  CA 
843:  P  R  N  V  G  W  K  D  K  V  S  Y  R  W  F  L  Q  H  R  P 
2761:  CAAGT  CG  GCTACAT  CAGAGCCAGAT~TAT~AAGGCACCGAGCTGGTGG CTGA  CT  CTGGA 
863:  Q  V  G  Y  I  R  A  R  F  u  E  G  T  E  L  V  A  D  S  G 
2821:  GT  CACTGTGGACAC  CAC  CATG  CGAGGAGGAAGACTG  GGAGTATTCTGCTTTTCACAGGAA 
883:  V  T  V  D  T  T  M  R  G  G  R  L  G  V  F  C  F  S  Q  E 
2881:  AACATAATTTGGT  C  CAAT  CTGAAATACCGGTGT~TGATACAATC CCAGAGGATTTC  CAG 
903:  N  I  I  W  S  N  L  K  Y  R  C  ~  D  T  I  P  E  D  F  Q 
2941:  G  CAT~TCAAG  CACAAC~'FFF~'CCAGT~CAGAACCCACACAATATCCGGTGATT~I~r 
923:  A  F  Q  A  Q  Q  F  S  S 
3001:  TTTTGTGA~-,'~:FFFIT~TGTAGTAATATGAGAAAACGTTATTTT  CATG  CAG  CCTTGTTTT 
3061:  CTACC~CTGTACAATAATGTCTGTAAAAT~u~AA~R~GATACAAAAA~AGA~ 
Figure 3. 
61.4%  identical to the type 3 repeats of human thrombo- 
spondin-1 (Fig. 4). The consensus sequence and overall or- 
ganization of the type 3  repeats of thrombospondin-4 are 
equivalent to thrombospondin-1, with the second and fourth 
type 3  repeats  being truncated after the second cysteine. 
Thrombospondin-4 contains four amino acids (PPGP) at the 
end of  the sixth type 3 repeat that do not align with sequences 
in thrombospondin-1 or 2. 
Alignment  of  the  COOH-terminal  of  the  Xenopus 
thrombospondin-4 sequence with the last 227 amino acids of 
human thrombospondin-1 reveals that 60.8 % of the amino 
acids  are  identical and no  insertions or deletions are re- 
quired.  The  thrombospondin-4  sequence  includes  fifteen 
amino acids that extend beyond the stop codon for human 
thrombospondin-1.  The  cysteine  residue  in  position  898 
aligns with a valine residue in thrombospondin-1 and 2. Be- 
cause  thrombospondin-4  has  an  odd  number  of cysteine 
residues in the predicted mature peptide, it is possible that 
cysteine(898) has a free sulfhydryl group. 
A.  Type  2  Repeats  of Thrombospondln-4: 
PRCDATS --  -CFRGVRCI DTEGGFQ-CGPCPEGYTG  ............. NGVICTDV 
DECRL-  -NP-CFLGVRCINTS  PGFK-CESCPPGYTGSTIQGIGINFAKQNKQVCTDT 
NECENGRNGGCTSNSLCINTMGSFR-  CGGCKPGYVG ............ DQIKGCKPE 
KSCRHGQNP-CHASAQCSEEKVGDVTCT-CSVGWAG  ............. NGYLCGK 
B.  Type  3  Repeats  of Thrombospondin-4: 
DNCVYVPNSGQEDTDKDN  I  GDACDE-  -DADGDGI  LNEQ 
DNCVLAAN I  DQKNSDQDI FGDAC 
DNCRLTI2/NDQRDTDNDGKGDACDD--  DMDGDG  I  KNI  L 
DNCQRVPNVDQKDKDGDGVGDI  C 
DSCPDI  INPNQSDI DNDLVGDS  CDTNQDS  DGDGHQDST 
DNCPTVINSNQLDTDKDGIGDECDD-  -  DDDNDGI  PDTVPPGP 
DNCKLVPNPGQE DDNNDGVGDVCEA- -DFDQDTVI  DRI 
D.C  ....  N..Q.D.D.D..GD.C  ....  D.D.D  ......  Consensus 
DNC  ....  N..Q.D.D.D..GD.C  ....  D.D.D  ......  TSP-I  and  2  Consensus 
Figure 4.  The amino acid sequence of the type 2 (A) and 3 (B) 
repeats of thrombospondin-4. The amino acid sequences for the 
four  type  2  repeats P(217)-K(394) and  seven type  3  repeats 
(D[416]-I[647])  have been  aligued.  The  positions of gaps ~ 
marked by dashes. The consensus sequence for the type 3 repeats 
of Xenop~ thmmbospondin-4 is compared to that for human and 
mouse thrombospondin-1 and chicken thrombospondin-2 at the 
bottom of the figure. The underline indicates that an N occupies 
one of the positions that is occupied by a D. 
Figure  5. Developmental expression of thrombospondin-4 mRNAs 
during Xenopus development as determined by RNase protection 
analyses.  Ten embryo equivalents  total mRNA per lane were by- 
bridized with a 3~P-labeled thrombospondin-4 antisense transcript 
synthesized in vitro. EFI-,~ mRNA analysis is included as a control 
for RNA loading. The relative stage-specific  levels of EFI-,v shown 
here are equivalent to those described by Krieg et al. (1989).  Em- 
bryos were staged according to Nieuwkoop and Faber (1967). Stage 
8 corresponds to the mid-blastula, which is marked by the onset 
of  zygotic transcription in Xenopus  (Newport and Kirschner, 1982). 
(P),  probe alone, unhybridized transcript,  no RNAse;  (t) tRNA 
control lane, no protected fragments after RNAse digestion. Stages 
include: (1) fertilized egg, (8) mid-blastula, 00-12) early-late gas- 
trula,  07) neurula, (25-35) tailbud stages,  (45)  feeding tadpole. 
Thrombospondin-4 protected fragment is ,,o300 nucleotides. EFI-a 
protected fragment is ,x,75 nucleotides. Full length EFI-c~  probe (90 
nucleotides) is not shown. 
Expression of Thrombospondin-4 
during Xenopus Development 
RNAse protection analysis has been used to establish the 
temporal  pattern  of thrombospondin-4  expression during 
Xenopus development (Fig. 5). 10 embryo equivalents of fer- 
tilized eggs and representative developmental stages have 
been  hybridized with  32p-labeled antisense  thrombospon- 
din-4  and  EFI-oL transcripts  followed by  digestion  with 
RNAse as described in Materials and Methods. EFl-ot has 
been included as a control for RNA loading (Krieg et al., 
1989).  No  thrombospondin-4  mRNA is  detected in egg, 
cleavage stage, blastula or gastrula stage embryos, even after 
prolonged exposure. These data indicate that thrombospon- 
din-4  is  not maternally stored  in Xenopus. Furthermore, 
thrombospondin-4 transcripts are not among those mRNAs 
synthesized at the onset of zygotic transcription, which com- 
mences at the mid-blastula stage in Xenopus  (Newport and 
Kirschner, 1982).  Initial expression of thrombospondin-4 is 
observed during neurulation (Fig.  4,  stage 17).  Levels of 
mRNA expression increase ,~twofold during tailbud stages 
but decrease by the feeding tadpole stage (Fig. 5, stages 25, 
35, and45). 
Expression of Thrombospondin-4 in Adult 
Human 1Issues 
A Northern blot of poly A+ selected RNA from eight adult 
human tissues is shown in Fig. 6.  The size of the human 
thrombospondin-4 message is  3.4  kb.  Thrombospondin-4 
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architecture  of  thrombospondin-4  is  shown below that  of 
thrombospondin-1 or 2.  The NH2 terminal is to the left and the 
COOH terminal is to the right.  Whereas the NH2-terminal do- 
mains are similar in size, they share very little sequence homology. 
Two interchain disulfides of thrombospondin-1 and 2 are depicted 
as vertical lines between the NH~-terminal  domain and the region 
of homology with procollagen. Whereas two cysteine residues are 
present in a similar location in thrombospondin-4, the structure of 
the  protein that contains the thrombospondin-4 polypeptide re- 
mains to be determined. 
Figure 6. The expression of thrombospondin-4 in adult human tis- 
sue. A northern blot ofpoly A + RNA from adult human heart (a), 
brain (b), placenta (c), lung (d), liver (e), skeletal muscle (f), kid- 
ney (g), and pancreas (h). The blot was probed with a 2.2-kb frag- 
ment of Xenopus thrombospondin-4. The positions and sizes (kb) 
of the markers are indicated on the left. 
shows  a restricted pattern of expression. High levels of ex- 
pression are observed in the heart and skeletal muscle (Fig. 
6). On longer exposures, a faint band is detectable in the tis- 
sue from the brain, lung and pancreas.  No expression has 
been detected in the placenta, liver or kidney. Comparable 
levels of the 2.0 kb form of/3-actin are observed in all of the 
lanes except the pancreas (Fig. 6). Because a considerable 
fraction  of  the  total  mRNA  in  the  pancreas  encodes 
preproinsulin and a-amylase, other mRNAs give a lower hy- 
bridization  signal.  Thus,  although  the  thrombospondin-4 
signal is weak in the pancreas, the relative level of expression 
may be significant. 
When the same blot is probed for thrombospondin-3, the 
strongest signal is observed in the lung (Fig. 6). The size of 
the thrombospondin-3 message is also 3.4 kb. Lower levels 
of thrombospondin-3 expression are observed in most of the 
lanes with the brain displaying the weakest hybridization sig- 
nal (Fig. 6). The adult lung tissue also produces the strongest 
signal when the blot is probed with a human thrombospon- 
din-1 probe (Fig. 6). Varying levels of thrombospondin-1 are 
observed in all of the tissues on the blot (Fig. 6). In this case, 
the principal message is 6.0 kb with faint bands at 4.5 and 
3.6 kb. 
Discussion 
In this paper, we have described a new member of the throm- 
bospondin gene family, designated thrombospondin-4. This 
member is similar to thrombospondin-1 and 2 in that the type 
3 (calcium-binding) repeats and the COOH-terminal domain 
are  conserved.  By contrast,  the  NH2-terminal  domain  is 
different from those  of thrombospondin-1  and 2,  and the 
regions of homology with procollagen and the type 1 repeats 
are absent (Fig.  7).  Thrombospondin-4 appears to have a 
more restricted pattern of tissue expression than the other 
members of the thrombospondin gene family. The highest 
levels  of thrombospondin-4  message  are  in  adult  human 
cardiac and skeletal muscle. These data indicate that specific 
tissues are capable of synthesizing specific forms of throm- 
bospondin and that biodiversity in the thrombospondin gene 
family is generated at a transcriptional level with multiple 
genes participating. 
The  difference in  tissue  distribution  between thrombo- 
spondin-3 and 4 was the first indication that they represented 
different gene products (Vos et al.,  1992). Several other ob- 
servations support this conclusion. The amino acid identity 
between the coding sequences of mouse thrombospondin-3 
and  Xenopus  thrombospondin-4  is  lower  than  would  be 
predicted based on the high level of sequence identity be- 
tween mouse and Xenopus thrombospondin-1 in an equiva- 
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al.,  1991). Thrombospondin-3 and 4 are also distinct in the 
size and sequence of the 3' untranslated  regions.  However, 
because our clones have been isolated from a Xenopus li- 
brary and the initial characterizations  of thrombospondin-3 
have been performed in the mouse and human,  differences 
in sequence or gene structure might be due to species varia- 
tions (Vos et al.,  1992). Using oligonucleotide  primers that 
are based on the Xenopus sequence,  we have isolated and se- 
quenced a human thrombospondin-4 clone (J.  Lawler,  M. 
Duquette and K. McHenry, unpublished data).  This estab- 
lishes that all four forms of thrombospondin are present in 
the human genome. We are currently mapping the thrombo- 
spondin-4 gene in the human and mouse genomes. 
The overall molecular architecture of  thrombospondin-4 is 
similar to that of thrombospondin-1  and 2 in that the NH2 
and COOH-terminal portions do not contain multiple copies 
of sequence motifs and are not homologous to other proteins 
in the database.  When the database is searched with the 
COOH-terminal  domain  of thrombospondin-4,  only  sig- 
nificant homology with thrombospondin-1  and 2 is detected. 
However, a search with the first 282 amino acids of the se- 
quence reported here fails to identify thrombospondin-I  and 
2. This gradient of homology seems to represent a general 
feature of the thrombospondin gene family:  the levels  of 
identity between the thrombospondin-1  sequences in the hu- 
man and mouse, or the thrombospondin-1  and 2 sequences 
in the mouse, are significantly  greater at the 3' end of the 
genes. 
The  molecular  architecture  of the  central  portion  of 
thrombospondin-4 is distinct from that of thrombospondin-1 
or 2 (Fig. 7). Whereas the type 2 and type 3 repeats are pres- 
ent in all of the forms of thrombospondin that have been se- 
quenced to date,  thrombospondin-4 lacks the region of ho- 
mology  with  procollagen  and  the  type  1  repeats.  This 
suggests that the divergence  of thrombospondin-4  from the 
branch that  gave rise to thrombospondin-1  and 2 occurred 
before the exon shuffling events that led to the insertion  of 
the region  of homology with procoUagen  and the type  1 
repeats.  We have proposed that  this  gene duplication  oc- 
curred 925 million years ago (J. Lawler et al.,  1993). The 
thrombospondin-1  and 2 branches appear to have diverged 
583 million years ago (J. Lawler et al., 1993). By this time, 
the region of homology with procollagen and the type  1 
repeats were apparently present.  This proposal is consistent 
with the existence of the type 1 repeats in the invertebrate, 
C. elegans (Leung-Hagesteijn  et al.,  1992). In vitro muta- 
genesis experiments  and expression  of variant  forms of the 
thrombospondin-1  polypeptide indicate that the region of ho- 
mology with  procollagen  is  involved  in  trimer  assembly 
(Lawler  et  al.,  1992).  The  absence  of this  region  from 
thrombospondin-4 may indicate that this molecule is not tri- 
meric. 
Whereas thrombospondin-1  and 2 have three type 2, EGF- 
like repeats,  thrombospondin-4 has four type 2 repeats.  A 
proposed consensus sequence for B-hydroxylation is similar 
to a sequence that is found in the second type 2 repeat of all 
of the members of the thrombospondin gene family (Sterdlo 
et al.,  1988).  This  sequence is found between the cysteine 
residues at positions 312 and 324 ofXenopus thrombospon- 
din-4  (Fig.  3).  The asparagine  at position  314  would be 
predicted to be/~-hydroxylated. In thrombospondin-4,  the 
consensus sequence for/~-hydroxylation  is also found in the 
first and third type 2 repeats (Fig. 3). The only variation from 
the consensus sequence is the insertion of an additional resi- 
due between the fourth and fifth  cysteine residues in the 
thrombospondin type 2 repeats.  Human thrombospondin-1 
has been reported to contain erythro-/~-hydroxyasparagine 
(Przysiecki et al.,  1987). In factor IX and protein C, ~hy- 
droxylation of an aspartic  acid residue of the EGF-like do- 
main is involved in calcium binding  to this domain (Ohlin 
et al., 1988; Hanford et al., 1991). Mutation of the aspartic 
acid  to  asparagine  in  the  EGF-like  repeat  of factor  IX 
markedly reduces calcium binding.  However, if a glutamic 
acid residue is present in a specific position that is upstream 
of  the asparagine,  this repeat is able to support calcium bind- 
ing (Fig.  3).  This has been designated a type II consensus 
sequence by Hanford and co-workers (1991). All of  the mem- 
bers of the thrombospondin gene family that have been se- 
quenced to date contain this motif (Fig. 2). These data sug- 
gest that  the  second EGF-like repeat of thrombospondin 
contains a calcium-bindiag site that has been conserved dur- 
ing evolution. 
Thrombospondin-4 mRNA is expressed early in embryo- 
genesis,  suggesting a role for this protein in development. 
The highest levels of thrombospondin-4  expression  that are 
observed coincide with the appearance of the major organ 
systems and tissue types in the embryo. These events include 
the formation of the heart, vascular system and skeletal mus- 
cle. Interestingly,  after reaching  maximal levels of expres- 
sion during tailbud stages a reproducible drop in thrombo- 
spondin-4  mRNA levels  is  noted by the  feeding  tadpole 
stage. Further analysis will be required to determine the spa- 
tial expression of  both thrombospondin-4  mRNA and protein 
during these stages using in situ hybridization  and immuno- 
histochemical methods.  However,  given the timing  of ex- 
pression in the embryo and the adult tissue distribution  of 
thrombospondin-4  mRNA (Figs. 5 and 6), it is reasonable 
to propose that  thrombospondin-4 may have an important 
function in heart and muscle morphogenesis.  Immunocyto- 
chemistry with monoclonal and polyclonal antibodies that 
have been prepared against human platelet thrombospondin 
indicates that thrombospondin(s)  are widely expressed in the 
developing mouse embryo (O'Shea and Dixit, 1988; Corless 
et al.,  1992). 
The data presented laere identify a fourth member of the 
thrombospondin gene family. Comparisons of the sequences 
ofXenopus thrombospondin-4  with mouse thrombospondin- 
3 suggest that they were produced by a gene duplication  that 
occurred before the gene duplication  that  separated  their 
branch from the thrombospondin-1  and 2 branch (J. Lawler 
et al.,  1993).  The sequences suggest that the type-2 and 3 
repeats and the COOH-terminal domain are conserved and 
therefore, serve a function that is common to all of the mem- 
bers of the thrombospondin gene family.  By contrast,  the 
NH2-terminal  domain,  the regions of homology with pro- 
collagen and the type 1 repeats may have tissue-specific func- 
tions. These data indicate that thrombospondin-4 has activi- 
ties  in  common  with  thrombospondin-1  and  2,  that  are 
mediated by the type 2 and type 3 repeats or the COOH- 
terminus,  and also has unique functions that are mediated by 
the divergent  NH2-terminai  domain. Assuming  that throm- 
bospondin-4 is a secreted protein, as the presence of an ap- 
parent signal sequence indicates,  it is likely that its interac- 
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will be different from those of thrombospondin-I and 2. The 
ability of thrombospondin-I to interact with other extracellu- 
lar matrix and with the cell surface components has been lo- 
cated  to the 70,000-D  chymotryptic  fragment  that corre- 
sponds to the procollagen homology region, and the type 1 
and type 2 repeats (Lawler et al., 1986). The type 1 repeats 
contain consensus heparin-binding sequence motifs and in- 
deed bind heparin (Guo et al.,  1992). 
For thrombospondin-1, it is known that cell-binding  activ- 
ity involves the amino-terminal heparin-binding domain; the 
CSVTCG sequence that is located within the type 1 repeats; 
the RGD sequence that is located within the last type 3 re- 
peat,  and the COOH-terminal  domain (Asch et al.,  1991; 
Kosfeld et al.,  1991; Stomski et al.,  1992). These sites are 
also present in thrombospondin-2.  Because Xenopus throm- 
bospondin-4 does  not contain the CSVTCG or RGD  se- 
quences, and possibly does not bind heparin, it is clear that 
its  interactions  with cells  will be different  from those of 
thrombospondin-1 and 2. Efforts are currently under way to 
determine  if thrombospondin-4  is indeed a cell  adhesion 
molecule. Such studies will yield information regarding the 
functions of thrombospondin-4 and will also lead to fresh in- 
sights concerning the functions of the other members of the 
thrombospondin  gene family. 
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